Join us for the 6th Annual diaTribe Musings Panel Discussions
NEXT EVENT: Wednesday, July 14, 2021
Type 1 Diabetes Research 2021: Science, Hope and Clinical Reality
5:30-8:00pm EDT / 2:30-5:00pm PDT
While hopes of a cure have been present for decades, recent advancements have added new momentum to the conversation around type 1 diabetes cures and prevention. What does the cure pipeline look like? How does “prevention” and “delay” differ from typical notions of a cure and what does it all mean for people with type 1? What is the role of patient screening in the development of these therapies and what challenges does it present? This panel includes industry experts working on the most promising approaches to confronting type 1 diabetes.
Panel discussion with Q&A from 5:30-7:00pm EDT / 2:30-4:00pm PDT, with Networking and Expo Booths open beginning 30 minutes prior. Stay on following the panel from 7:00-8:00pm EDT / 4:00-5:00pm PDT for an interactive community session led by diaTribe's phenomenal community manager, Cherise Shockley! Networking and Expo Booths will also remain open following the panel.
Our highly-regarded speakers are Henry Anhalt, Endocrinologist & Executive Director of Medical Affairs, Provention Bio; Francine Kaufman, Endocrinologist & Chief Medical Officer, Senseonics, Inc.; Felicia Pagliuca, Scientist & Vice President/Disease Area Executive, Type 1 Diabetes, Vertex; Georgea Pasedis, Doctor of Pharmacy & Vice President, Head of Medical Affairs North America, Dompé. The panel will be moderated by Endocrinologist, Independent Consultant and diaTribe board member Alan Moses.
Henry Anhalt, Endocrinologist & Executive Director of Medical Affairs, Provention Bio
Dr. Henry Anhalt is a board-certified pediatric endocrinologist and physician scientist who has served in executive roles with increasing responsibility during his career spanning academia, bio- pharma, non-profit and most recently at Provention Bio where he serves as executive director of medical affairs. Dr. Anhalt attended the New York College of Osteopathic Medicine (DO). Upon graduation he did a rotating internship at The Brookdale University Hospital Center (SUNY Downstate), and his pediatric residency and chief residency at Winthrop University Hospital (SUNY Stony Brook). Dr. Anhalt completed his pediatric endocrinology fellowship at Lucille Packard Children’s Hospital at Stanford University. After returning to the east coast, Dr. Anhalt served as division chief at the Brooklyn Hospital Center, Maimonides Children’s Hospital, and the St. Barnabas Medical Center. In 2008 he joined Animas corporation (Johnson and Johnson) where he was Chief Medical Officer and responsible for the development of an artificial pancreas system. While at Sanofi he served as North American medical affairs lead responsible for launching Toujeo, which was followed by his appointment as Chief Medical Officer at the T1D Exchange. He joined Science 37, a decentralized clinical trial company where he served a vice president and joined Provention Bio in December 2020.Dr. Anhalt has served on and chaired several committees within the Endocrine Society including the Hormone Health Network, and Advocacy and Public Outreach Core Committee. Most recently he was appointed to the Endocrine Society Board of Directors. He serves on the editorial board of Endocrine News, has authored over 40 original manuscripts, dozens of abstracts, consensus statements, textbook chapters and clinical reviews. He serves on the Board of Directors of Insulin for Life-USA which provides insulin and disease management supplies free of charge to emerging countries and in the US during periods of natural disasters. In addition, he sits on the Board of Directors of Camp Nejeda for children with T1D. He maintains a pediatric endocrinology practice in Hackensack, NJ.
Francine Kaufman, Distinguished Professor Emerita of Pediatrics, Keck School of Medicine of the University of Southern California; Advisory Board, diaTribe
Francine R. Kaufman, M.D. is the Chief Medical Officer of Senseonics, Inc. Previously, she was the Chief Medical Officer and Vice President of Global Regulatory, Clinical and Medical Affairs at Medtronic Diabetes from 2009-2019. She is a Distinguished Professor Emerita of Pediatrics and Communications at the Keck School of Medicine and the Annenberg School of Communications at the University of Southern California. She is an attending physician at Children’s Hospital of Los Angeles, where she served as Director of the Comprehensive Childhood Diabetes Center, and head of the Center for Endocrinology, Diabetes and Metabolism. She has authored over 285 peer-reviewed and invited articles, and numerous books and book chapters, including Diabesity (Bantam, 2005), The Medical Management of Type 1 Diabetes (American Diabetes Association, 2008), The Insulin Pump and Continuous Glucose Monitoring Book: For Patients, Parents and Caregivers (American Diabetes Association, 2017) and Rhythms (a novel) (CKI Publisher, 2015). She was funded by the National Institutes of Health for 3 decades and elected membership in the National Association of Medicine (formerly the Institute of Medicine) of the National Academies of Science. Dr. Kaufman was national president of the American Diabetes Association from 2002-2003. She was recognized by the California State Senate for her work in banning sodas in LA Unified School District (2004) and appointed by Congress as a Local Legend with the American Woman’s Medical Association. In 2009, she received a Telly and CINE for starring in and co-authoring the Discovery Health Documentary, Diabetes: The Global Epidemic. She has been the medical director of diabetes camps in Southern California, Ecuador and Haiti for over 30 years.
Felicia Pagliuca, Scientist & Vice President/Disease Area Executive, Type 1 Diabetes, Vertex
Dr. Felicia Pagliuca joined Vertex in 2019 and is the company’s Vice President and Disease Area Executive for Type 1 Diabetes. She is also a member of the Vertex Cell and Genetic Therapies leadership team. In this role, Dr. Pagliuca leads the cross-functional type 1 diabetes disease strategy team and is responsible for driving the strategy and execution of the program. Previously, Dr. Pagliuca co-founded Semma Therapeutics, which was acquired by Vertex in 2019. While at Semma, she served as Vice President of Cell Biology Research and Development, where she led the development of novel cell therapies for the treatment of type 1 diabetes. Prior to Semma, Dr. Pagliuca worked with Dr. Douglas Melton to discover how to generate stem cell-derived pancreatic beta cells, and is one of the inventors of Semma’s key technology. Dr. Pagliuca received a B.S. from Duke University and a Ph.D. from Cambridge University where she was a Marshall Scholar. She completed her postdoctoral fellowship with Dr. Melton at the Harvard Stem Cell Institute.
Georgea Pasedis, Doctor of Pharmacy & Senior Vice President, Global Head of Medical Affairs, Dompé
Georgea joined Dompé in 2018 to build the U.S. Medical Affairs team. Georgea now leads the Global Medical Affairs organization which includes the MSL team, medical information, communications, and operations as well as post-marketing clinical development and operations for both Ophthalmology and Type 1 Diabetes. She has extensive experience and clinical expertise in Ophthalmology, Diabetes, Pain, Neurology, Oncology and Cardiology and has held multi-roles spanning both medical and commercial organizations. She received her Doctor of Pharmacy from Massachusetts College of Pharmacy and Health Sciences and is a licensed pharmacist in Massachusetts. Georgea is a certified immunizing pharmacist and certified diabetes patient educator. She sits on the Board of Trustees for the Hellenic Nursing and Rehabilitation Center and Hellenic Women’s Benevolent Association.
Alan Moses, Endocrinologist, Independent Consultant & Board Member, The diaTribe Foundation
Dr. Alan Moses is an independent consultant for the pharmaceutical and biotechnology sector. Trained in internal medicine and endocrinology, he spent the early part of his academic career at Harvard doing bench and clinical research and clinical care. Dr. Moses co-founded and directed the Clinical Investigator Training Program at Beth Israel Deaconess-Harvard Medical School-MIT. From 1998 to 2004, Dr. Moses served as Senior Vice President and Chief Medical Officer of the Joslin Diabetes Center with specific responsibility for the Joslin Clinic. He joined Novo Nordisk in 2004. During his 14 years at Novo Nordisk, Dr. Moses served in multiple roles beginning as Associate Vice President of Medical Affairs in the US and rising to the position of Senior Vice President and Global Chief Medical Officer working in Copenhagen. Dr. Moses earned his MD from the Washington University School of Medicine in St. Louis, worked for three years at the National Institutes of Health, completed his clinical endocrine/diabetes training at Tufts New England Medical Center, and studied Health Care Strategy at Harvard Business School. He retired from Novo Nordisk in June 2018.
About diaTribe Musings
Previously known as Musings Under the Moon, when it was a single live event at the ADA Scientific Sessions, diaTribe Musings is now one of The diaTribe Foundation's most treasured ongoing virtual programs, engaging a diverse audience in thought-provoking dialogue and providing an opportunity to connect healthcare providers, business leaders, people with diabetes, advocates, families, entrepreneurs, and policymakers. Musings tickets are complimentary thanks to the generous support of our sponsors. We welcome anyone interested in learning about the massive shifts and opportunities occurring in the world of diabetes. Please spread the word and share this event with anyone interested in learning more about diabetes. Join the conversation on Twitter with #diaTribeMusings.
Past Musings Events